Rochlin Kate 4

What Happened
Kate Rochlin, President and Chief Operating Officer of IN8BIO (INAB), was granted a derivative award covering 80,000 shares on February 4, 2026. The grant is reported at $0.00 per share (no cash paid at grant). This was an award/option-style grant, not an open-market purchase or sale, so it does not represent immediate sale or transferable shares.

Key Details

• Transaction date: February 4, 2026; Form 4 filed February 6, 2026 (timely file).
• Transaction type/code: A — Award/Grant (derivative security).
• Amount: 80,000 shares (derivative); reported price $0.00.
• Vesting (footnote): 25% vests on February 4, 2027; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan or tax-withholding note disclosed in the provided details.

Context
This is a standard equity compensation award to an executive and represents future potential ownership subject to vesting and continued employment. Because it is a derivative grant (option/award) with a multi-year vesting schedule, it is not an immediate market signal like a buy or sale; it primarily reflects standard executive compensation practices.